- Financial momentum for Nutriband is indicated by its recent Q1 financial report
- Progress continues development of proprietary AVERSA(TM) Fentanyl, notes quarterly report
- AVERSA(TM) Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch
A wave of positive developments continues to build momentum for Nutriband (NASDAQ: NTRB), with recent capital funding, strategic partnerships and an expanded intellectual property portfolio reinforcing its bid to lead in the development of safer transdermal therapies. Nutriband is positioning itself at the forefront of abuse-deterrent drug delivery by advancing its Aversa platforms, notably its flagship fentanyl patch and buprenorphine candidates.
Financial momentum for Nutriband is indicated by its recent Q1 financial report (ibn.fm/8R0ca), which noted that the company posted record Q1 2025 revenue of $667,000 — a 63% year-over-year increase — driven by expansion in its kinesiology tape manufacturing via subsidiary Pocono Pharma and growing retail sales at Target, Walmart, Walgreens and CVS.
The company also reported that it is continuing to expand its kinesiology tape output through its Pocono Pharma subsidiary, with a continued focus on penetration pricing to gain a foothold with some of the industry’s largest brands. “Progress continues on the development of AVERSA Fentanyl, with the company formalizing an exclusive product development partnership with Kindeva Drug Delivery,” the report stated. “The formalized partnership with Kindeva Drug Delivery reflects a commitment to shared development costs in exchange for milestone payments, enabling Nutriband to advance its innovative transdermal drug-delivery solutions towards regulatory approval and commercialization.”
The company’s momentum began last year with a notable milestone: the closing of an $8.4 million private placement earmarked to fund AVERSA(TM) Fentanyl’s full-scale commercial development ahead of an expected 2025 NDA submission (ibn.fm/9SZ8B). The company is working with Kindeva, an FDA-approved contract development and manufacturing organization (“CDMO”), to integrate its transdermal abuse-deterrent technology into Kindeva’s existing fentanyl patch. The goal is a best-in-class 505(b)(2) application supported by a single phase 1 human abuse-potential study, bypassing the usual phase 2 and 3 trials.
“AVERSA Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches,” the company stated. “AVERSA(TM) Fentanyl has the potential to reach peak annual U.S. sales of $80 million to $200 million.”
Alongside fentanyl, Nutriband is advancing AVERSA(TM) Buprenorphine, projected to achieve peak U.S. sales between $70 million and $130 million upon approval (https://ibn.fm/mIHdw). Like its counterpart, AVERSA Buprenorphine benefits from Nutriband’s scalable abuse-deterrent platform, and the technology is being positioned for global patent protection.
Nutriband’s forward trajectory is clear: combining transdermal innovation with abuse-deterrent science to meet critical public health needs. With its commercial infrastructure and pipeline expansion, the company is paving a path toward safer opioid management. As the opioid crisis continues, Nutriband’s leadership in transdermal patch technology offers a promising model for improving patient safety without sacrificing efficacy.
For more information, visit the company’s website at www.Nutriband.com.
NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB
